K145_hydrochloride_DataSheet_MedChemExpress
MK2-IN-1_hydrochloride_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jul.-24-2017Print Date:Jul.-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :MK2-IN-1 (hydrochloride)Catalog No. :HY-12834ACAS No. :1314118-94-91.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MK2 InhibitorFormula:C27H26Cl2N4O2Molecular Weight:509.43CAS No. :1314118-94-94. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Pink to red (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Naglazyme（galsulfase）（抗生物）商品说明书
Naglazyme® (galsulfase)(Intravenous)Document Number: MH-0084 Last Review Date: 02/01/2022Date of Origin: 11/28/2011Dates Reviewed: 12/2011, 02/2013, 02/2014, 12/2014, 10/2015, 10/2016, 10/2017, 10/2018, 02/2019,02/2020, 02/2021, 02/2022I.Length of AuthorizationCoverage will be provided for 12 months and may be renewed.II.Dosing LimitsA.Quantity Limit (max daily dose) [NDC Unit]:•Naglazyme 5 mg vial: 23 vials per 7 daysB.Max Units (per dose and over time) [HCPCS Unit]:•115 billable units every 7 daysIII.Initial Approval Criteria 1Coverage is provided in the following conditions:•Patient is at least 5 years of age; AND•Documented baseline 12-minute walk test (12-MWT), 3-minute stair climb test (3-MSCT), and/or pulmonary function tests (e.g., FEV1, etc.); AND•Documented baseline value for urinary glycosaminoglycan (uGAG); ANDMucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) † Ф1,4,5•Patient has a definitive diagnosis of MPS VI as confirmed by the following:o Detection of pathogenic mutations in the ARSB gene by molecular genetic testing; ORo Arylsulfatase B (ASB) enzyme activity of <10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes; AND▪Patient has normal enzyme activity of a different sulfatase (excluding patients with Multiple Sulfatase Deficiency [MSD]); AND▪Patient has an elevated urinary glycosaminoglycan (uGAG) level (i.e. dermatan sulfate or chondroitin sulfate) defined as being above the upper limit of normal bythe reference laboratory†FDA-approved indication(s); ‡Compendia recommended indication(s); ФOrphan DrugIV.Renewal Criteria 1,4,5Coverage can be renewed based on the following criteria:•Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified insection III; AND•Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: anaphylaxis and hypersensitivity reactions, immune-mediated reactions, acute respiratorycomplications associated with administration, acute cardiorespiratory failure, severeinfusion reactions, spinal or cervical cord compression, etc.; AND•Disease response with treatment as defined by improvement or stability from pre-treatment baseline by the following:o Reduction in uGAG levels; AND▪Improvement in or stability of 12-minute walk test compared (12-MWT); OR▪Improvement in or stability of 3-minute stair climb test (3-MSCT); OR▪Improvement in or stability of pulmonary function testing (e.g., FEV1, etc.)V.Dosage/Administration 1Indication DoseMucopolysaccharidosis VI(MPS VI, Maroteaux-Lamy Syndrome) 1 mg/kg administered as an intravenous (IV) infusion oncea weekVI.Billing Code/Availability InformationHCPCS Code:•J1458 – Injection, galsulfase, 1 mg; 1 billable unit = 1 mgNDC:•Naglazyme 5 mg per 5 mL solution; single-use vial: 68135-0020-xxVII.References1.Naglazyme [package insert]. Novato, CA; BioMarin Pharmaceutical Inc.; December 2019.Accessed January 2022.2.Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI.Pediatrics. 2007 Aug;120(2):405-18.3.Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief reviewand guidelines for treatment. Genet Mol Biol. 2010 Oct;33(4):589-604. Epub 2010 Dec 1.4.Vairo F, Federhen A, Baldo G, et al. Diagnostic and treatment strategies inmucopolysaccharidosis VI. Appl Clin Genet. 2015 Oct 30;8:245-55.5.Valaannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. Orphanet J RareDis. 2010; 5: 5.6.Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy formucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled,multinational study of recombinant human N-acetylgalactosamine 4-sulfatase(recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. JPediatr. 2006 Apr;148(4):533-539.Appendix 1 – Covered Diagnosis CodesICD-10 ICD-10 DescriptionE76.29 Other mucopolysaccharidosesAppendix 2 – Centers for Medicare and Medicaid Services (CMS)Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National CoverageDetermination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: https:///medicare-coverage-database/search.aspx. Additional indications may be covered at the discretion of the health plan.Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/AMedicare Part B Administrative Contractor (MAC) JurisdictionsJurisdiction Applicable State/US Territory ContractorE (1) CA, HI, NV, AS, GU, CNMI Noridian Healthcare Solutions, LLCF (2 & 3) AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ Noridian Healthcare Solutions, LLC5 KS, NE, IA, MO Wisconsin Physicians Service Insurance Corp (WPS)6 MN, WI, IL National Government Services, Inc. (NGS)H (4 & 7) LA, AR, MS, TX, OK, CO, NM Novitas Solutions, Inc.8 MI, IN Wisconsin Physicians Service Insurance Corp (WPS) N (9) FL, PR, VI First Coast Service Options, Inc.J (10) TN, GA, AL Palmetto GBA, LLCM (11) NC, SC, WV, VA (excluding below) Palmetto GBA, LLCNovitas Solutions, Inc.L (12) DE, MD, PA, NJ, DC (includes Arlington &Fairfax counties and the city of Alexandria in VA)K (13 & 14) NY, CT, MA, RI, VT, ME, NH National Government Services, Inc. (NGS)15 KY, OH CGS Administrators, LLC。
CAS1204313-51-8_Icotinib Hydrochloride_MedBio相关资料
在体外激酶测定中，将2.4 ng /μLEGFR蛋白与32 ng /μLCrk在含有1μM冷ATP和1μCi32P-γ-ATP的25μL激酶反应缓冲液中混合。将混合物与Icotinib在0,0.5,2.5,12.5或62.5nM下在冰上温育10分钟，然后在30℃温育20分钟。用SDS样品缓冲液在100℃猝灭4分钟后，通过在10％SDS-PAGE凝胶中电泳分离蛋白质混合物。然后暴露干燥的凝胶以检测放射性。量化由软件[1]执行。
CAS
1、产品物理参数：
常用名
凯美纳
英文名
Icotinib Hydrochloride
CAS号
1204313-51-8
分子量
427.881
密度
无资料
沸点
无资料
分子式
C22H22ClN3O4
熔点
无资料
闪点
无资料
2、技术资料：
体外研究
与Iconitib在0.5μM孵育导致激酶活性抑制分别为91％，99％，96％，61％和61％。 Iconitib抑制A431和BGC-823 A549，H460和KB细胞系的增殖，IC50分别为1,4.06,12.16,16.08,40.71μM。当用88种激酶进行分析时，Icotinib仅对EGFR及其突变体显示出有意义的抑制活性。 Icotinib阻断人表皮样癌A431细胞系中EGFR介导的细胞内酪氨酸磷酸化（IC50 = 45 nM）并抑制肿瘤细胞增殖[1]。
10mM (in 1mL DMSO)
≥98%
1172133-28-6
5mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
一种盐酸芬戈莫德的合成方法及其中间体
一种盐酸芬戈莫德的合成方法及其中间体盐酸芬戈莫德（hydrochloride fenclonine）是一种常用的神经调节剂，用于治疗抑郁症和精神病等疾病。
其合成方法一般涉及几个重要的中间体。
首先，盐酸芬戈莫德可以通过对双丙氨基甲苯（dipropyramine）的化学反应来合成。
这个过程包括如下几个步骤。
步骤一：双丙氨基甲苯首先通过酸催化剂在乙酸甲酯（acetic methyl ester）中饱和硝化，形成相应的硝基化合物。
此反应需要加入适量的浓硫酸和硝酸。
步骤二：接下来，硝基化合物通过氢氧化钠（sodium hydroxide）的作用，在醇溶剂中进行还原反应，得到相应的氨基化合物。
步骤三：经过还原反应得到氨基化合物后，通过对其进行氯化处理，生成氯莫衍生物。
此反应需要加入适量的氯化亚砜（thionyl chloride）和五氯硅烷（silicon tetrachloride）等试剂。
步骤四：氯莫衍生物通过将其与氨（ammonia）或二甲基胺（dimethylamine）反应，进行还原反应，得到芬戈基胺。
此反应需要在高压下进行，并在其中加入一定量的氢气气氛。
步骤五：最后，芬戈基胺与盐酸反应，生成最终的盐酸芬戈莫德。
以上所述的合成方法是盐酸芬戈莫德的一种较常用的合成方法。
虽然该方法中所使用的试剂较多，合成步骤较多，但是该方法具有可行性和高产率的特点。
此外，该方法还可以通过合理地选择和改进试剂和反应条件来改进产率和纯度。
盐酸芬戈莫德的中间体包括硝基化合物、氨基化合物、氯莫衍生物和芬戈基胺。
在合成过程中，这些中间体的选择和转化反应是非常关键的。
对这些中间体的制备和转化反应进行优化，可以有效提高盐酸芬戈莫德的产率和纯度。
总的来说，盐酸芬戈莫德是一种重要的神经调节剂，其合成方法包括多个步骤和中间体。
在合成过程中，对中间体的选择和反应条件的控制是非常重要的。
进一步的研究和改进可以提高盐酸芬戈莫德的合成效率和纯度，更好地满足临床需求。
1,5-脱水-D-山梨醇测定试剂盒(吡喃糖氧化酶法)产品技术要求九强
1,5-脱水-D-山梨醇测定试剂盒（吡喃糖氧化酶法）适用范围：用于体外定量测定人血清或血浆中的1,5-脱水山梨醇（1,5-AG）含量。
1. 产品型号/规格及其划分说明1.1 包装规格见表1。
表1 包装规格包装规格试剂1：2×45ml、试剂2：2×15ml试剂1：3×45ml、试剂2：3×15ml试剂1：1×60ml、试剂2：1×20ml校准品：1×2ml质控品(水平1)：1×2ml质控品(水平2)：1×2ml1.2 组成成分见表2。
表2 组成成分组成成分浓度试剂1：4-氨基安替1.5mmol/L比林己糖激酶4KU/L腺嘌呤核苷三磷酸1mmol/L丙酮酸激酶3KU/L磷酸烯醇式丙酮酸4mmol/L抗坏血酸氧化酶5KU/L防腐剂0.1%试剂2：过氧化物酶10KU/L吡喃糖氧化酶80KU/L羟基甲苯磺酰碘苯 4.5mmol/L防腐剂0.1%校准品：1,5-脱水-D-山梨醇，缓冲液基质100～200µmol/L质控品：1,5-脱水-D-山梨醇，缓冲液基质水平1：20～70µmol/L水平2：70~130µmol/L2.1 外观试剂1为无色澄清液体，目测不得有任何沉淀及絮状悬浮物；试剂2为黄色澄清液体，目测不得有任何沉淀及絮状悬浮物；校准品为无色到淡黄色澄清液体，目测不得有任何沉淀及絮状悬浮物；质控品为无色到淡黄色澄清液体，目测不得有任何沉淀及絮状悬浮物。
试剂盒标签标识清晰，外包装完整无损。
2.2 净含量试剂的净含量应不少于标称量。
2.3 试剂空白吸光度A546nm下测定空白吸光度应≤0.1000。
2.4 准确度与已上市产品进行比对试验：在[6.0，300.0] µmol/L区间内，相关系数r≥0.990，在[6.0，30.0] µmol/L区间内测定的偏差应不超过±3.0 µmol/L，在(30.0，300.0] µmol/L区间内测定的偏差应不超过±10%。
l-鸟氨酸盐酸盐的标准
L-鸟氨酸盐酸盐（L-Ornithine Hydrochloride）是一种氨基酸盐酸盐，常用于生物研究和实验分析。
其标准品通常按照相关标准进行生产和质量控制。
以下是关于L-鸟氨酸盐酸盐的一些参考标准：
1. 英国药典（BP）标准：L-鸟氨酸盐酸盐的标准品应符合英国药典中关于L-鸟氨酸盐酸盐的质量要求，包括性状、旋光度、重金属、含水量、干燥失重、灼烧残渣等指标。
2. 中国标准品网：L-鸟氨酸盐酸盐标准品货号为O695550，英文名为L-Ornithine Hydrochloride。
其质量应符合中国标准品网关于L-鸟氨酸盐酸盐的质量要求。
3. 检测方法：对于L-鸟氨酸盐酸盐的检测，可以参考GB/T 14751-2008《食品中氨基酸的测定离子交换色谱法》或GB/T 18902-2002《食品中氨基酸的测定紫外分光光度法》等方法。
这些方法可以用于测定L-鸟氨酸盐酸盐的含量。
4. 存储条件：L-鸟氨酸盐酸盐标准品应避光冷藏，以保证其质量和稳定性。
泛昔洛韦
密度：1.4g/cm3 熔点：102-104°C 沸 点 ： 5 5 0 . 2 ºC 闪 点 ： 2 8 6 . 6 ºC 折射率：1.628 外观：灰白色粉末 溶解性：易溶于丙酮或甲醇，难溶于乙醇或异丙醇
摩尔折射率：82.66 摩尔体积（cm3/mol）：239.8 等张比容（90.2K）：639.3 表面张力（dyne/cm）：50.4 极化率（10-24cm3）：32.77
进入人体内后迅速转变成喷昔洛韦，喷昔洛韦可被病毒编码的胸苷激酶磷酸化成OCV单磷酸，再经宿主的磷 酸化成为喷昔洛韦三磷酸盐，三磷酸盐在病毒感染的细胞内迅速形成，缓慢代谢，致半衰期延长，参与HBV DNAp的三磷酸鸟苷(Pgtp)竞争，并进入DNA，作用于DNA合成的起始和延伸步骤，抑制DNA的合成，对水痘-带状疱疹 病毒、单纯疱疹病毒1型和2型和HBV均有较强的抑制作用。
泛昔洛韦
药品
目录
01 化合物简介
03 药典信息
02 药品简介 04 安全信息
泛昔洛韦，是一种有机化合物，化学式为C14H19N5O4，是第二代开环核苷类抗病毒药，主要用于疱疹病毒感 染，尤其是带状疱疹。
化合物简介
基本信息 理化性质
分子数据 化学数据
化学式：C14H19N5O4 分子量：321.332 CAS号：-87-4
疏水参数计算参考值（XlogP）：无 氢键供体数量：1 氢键受体数量：8 可旋转化学键数量：9 互变异构体数量：3 拓扑分子极性表面积：122 重原子数量：23 表面电荷：0 复杂度：404 同位素原子数量：0 确定原子立构中心数量：0
药品简介
作用机理
药代动力学
不良反应
泛昔洛韦口服迅速吸收，生物利用度77%，在体内很快转达变为喷昔洛韦，t1/2约为2h，约60-65%经肾排出。 在水痘-带状疱疹病毒感染的细胞内有一个较长的半衰期（9-10小时），单纯疱疹病毒1型和2型感染的细胞内半 衰期分别为10小时和20小时。
盐酸西维美林半水合物的制备
王信见,等:盐酸西维美林半水合物的制备/2019年第10期收稿日期:2019⁃07⁃11作者简介:王信见(1976-),男,四川彭州人,高级工程师,研究方向:药物合成,E⁃mail :4207678@ ;通讯作者:但国蓉,讲师,E⁃mail :liroy@ 。
doi :10.3969/j.issn.1672-5425.2019.10.016王信见,朱小锋,喻威,等.盐酸西维美林半水合物的制备[J ].化学与生物工程,2019,36(10):10⁃10.WANG X J ,ZHU X F ,YU W ,et al.Preparation of cevimeline hydrochloride hemihydrate [J ].Chemistry &Bioengineering ,2019,36(10):10⁃10.盐酸西维美林半水合物的制备王信见1,朱小锋1,喻 威1,但国蓉2(1.重庆惠源医药有限公司,重庆400039;2.陆军军医大学军事预防医学系,重庆400038)摘 要:在叔丁醇钠催化下,将3⁃喹咛环酮盐酸盐(Ⅱ)与三甲基碘化亚砜反应生成三亚甲基喹咛环氧化物(Ⅲ),再通入硫化氢开环加成得到3⁃羟基⁃3⁃巯基亚甲基喹咛(Ⅳ),化合物Ⅳ与乙醛缩合后生成西维美林碱基(Ⅴ),化合物Ⅴ再与消旋樟脑磺酸成盐并经过多次精制得到高纯度西维美林樟脑磺酸盐(Ⅵ),化合物Ⅵ碱化后与氯化氢成盐得到目标产物盐酸西维美林半水合物(Ⅰ),总收率20.5%。
该合成方法反应条件温和、操作简单、周期短、收率高,利于工业化生产。
关键词:西维美林半水合物;高收率;制备中图分类号:TQ460.31 文献标识码:A 文章编号:1672⁃5425(2019)10⁃0001⁃03Preparation of Cevimeline Hydrochloride HemihydrateWANG Xinjian 1,ZHU Xiaofeng 1,YU Wei 1,DAN Guorong 2(1.Chongqing Huiyuan Pharmaceutical Co.,Ltd ,Chongqing 400039,China ;2.College of Preventive Medicine ,Army Medical University ,Chongqing 400038,China )Abstract :Compound(Ⅲ)is obtained through the reaction between 3⁃quinuclidinone hydrochloride(Ⅱ)and trime⁃thylsulfoxonium iodide in the precence of sodium tert⁃butoxide,then compound Ⅳis obtained through ring⁃opening and addition of compound(Ⅲ)with hydrogen sulfide,and compound Ⅴis obtained through condensation of compound Ⅳwith acetaldehyde.Moreover,high⁃purity compound Ⅵis obtained from compound Ⅴvia reaction with racemic cam⁃phorsulfonic acid,recrystallization for resolution.Furthermore,Cevimeline hydrochloride hemihydrate (Ⅰ)is obtained from compound Ⅵvia alkalization,salt⁃forming reaction with hydrogen chloride with the total yield of 20.5%.This syn⁃thetic method has advantages such as moderate conditions,simple operation,saving time,and high yield,which is favora⁃ble for industrial production.Keywords :Cevimeline hydrochloride hemihydrate;high yield;preparation 盐酸西维美林半水合物,英文名Cevimeline hydro⁃chloride hemihydrate,化学名(+/-)⁃顺式⁃2⁃甲基螺(1,3⁃氧硫杂环戊烷⁃5,3'⁃喹咛环)盐酸半水合物,由Snow Brand 制药公司研制,2000年3月在美国首次上市(商品名Evoxac),2001年在日本批准上市,随后相继在台湾、香港等地上市。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Inhibitors, Agonists, Screening Libraries
Data Sheet
BIOLOGICAL ACTIVITY:
K145 is a selective SphK2 inhibitor with an IC50 of 4.30±0.06 μM , while no inhibition of SphK1 at concentrations up to 10 μM.IC50 value: 4.3 uM [1]
Target: SphK2
in vitro: K145 inhibited the activity of SphK2 in a dose–dependent manner with an IC50 of 4.30±0.06 uM , while no inhibition of SphK1at concentrations up to 10 uM was observed. Lineweaver–Burk analysis revealed a Ki of 6.4±0.7 uM for SphK2 and indicated that K145is a substrate competitive inhibitor (with sphingosine). K145 accumulates in U937 cells, suppresses the S1P level, and inhibits SphK2.K145 also exhibited inhibitory effects on the growth of U937 cells as well as apoptotic effects in U937 cells, and that these effects may be through the inhibition of down–stream ERK and Akt signaling pathways [1].
in vivo: K145 also significantly inhibited the growth of U937 tumors in nude mice by both intraperitoneal and oral administration, thus demonstrating its in vivo efficacy as a potential lead anticancer agent [2].
References:
[1]. Liu K, et al. Biological characterization of 3–(2–amino–ethyl)–5–[3–(4–butoxyl–phenyl)–propylidene]–thiazolidine–2,4–dione (K145) as a selective sphingosine kinase–2 inhibitor and anticancer agent. PLoS One. 2013;8(2):e56471.
Product Name:
K145 (hydrochloride)Cat. No.:
HY-15779A CAS No.:
1449240-68-9Molecular Formula:
C 18H 25ClN 2O 3S Molecular Weight:
384.92Target:
SPHK Pathway:
Immunology/Inflammation Solubility:
10 mM in DMSO
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。